Home › Astrocytoma › California
Astrocytoma clinical trials in California
10 studies for Astrocytoma are looking for participants at sites in California.
Cities in California
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- City of Hope Comprehensive Cancer Center, Duarte
- Kaiser Permanente Dublin, Dublin
- and 21 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT07215910Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of California San Diego, La Jolla
- University of California, Los Angeles, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Los Angeles
- Research Site, San Francisco
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07544992Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT06815029The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- University of California, San Francisco, San Francisco
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 28, 2024 · NCT06283927The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- University of California, San Francisco, San Francisco
RecruitingObservational study
Up to age 90 · All sexes · Updated Feb 22, 2024 · NCT06273176The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- University of California, San Francisco (UCSF), San Francisco
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 22, 2024 · NCT06118723From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.